Cancer
Malignant Ovarian Neoplasm
CI-CAN-00003205Explore in graph →
Top-level684 active trials5 approved drugs83 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00003205Explore in graph →
Clinical trials
3,086 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (437)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00886691 | Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 2 | 150 | GOG FoundationNETWORK | 1 | Feb 4, 2022 | clinicaltrials |
| NCT02764333 | TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer | completed | Phase 2 | 29 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 30, 2021 |
| clinicaltrials |
| NCT02657928 | Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer | completed | Phase 2 | 40 | Mayo ClinicOTHER | 1 | Oct 26, 2021 | clinicaltrials |
| NCT00888615 | Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 2 | 58 | GOG FoundationNETWORK | 1 | Oct 20, 2021 | clinicaltrials |
| NCT01720173 | Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer | completed | Phase 2 | 30 | Gynecologic Oncology GroupNETWORK | 1 | Oct 20, 2021 | clinicaltrials |
| NCT01551745 | Salvage Ovarian FANG™ Vaccine + Bevacizumab | completed | Phase 2 | 5 | Gradalis, Inc.INDUSTRY | 1 | Oct 19, 2021 | clinicaltrials |
| NCT01853644 | Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer(TIVO) | completed | Phase 2 | 31 | Northwestern UniversityOTHER | 1 | Oct 12, 2021 | clinicaltrials |
| NCT02853318 | Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 40 | Roswell Park Cancer InstituteOTHER | 1 | Oct 6, 2021 | clinicaltrials |
| NCT03685695 | Physical Activity Monitored by Fitbit Charge 2 in Improving Quality of Life in Participants With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 2 | 9 | Roswell Park Cancer InstituteOTHER | 1 | Sep 2, 2021 | clinicaltrials |
| NCT02993705 | Trial On Trabectedin In The Treatment Of Advanced Uterine And Ovarian Carcinosarcoma (CS)(MITO 26) | completed | Phase 2 | 45 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Aug 25, 2021 | clinicaltrials |
| NCT01631552 | Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer | completed | Phase 1 / Phase 2 | 515 | Gilead SciencesINDUSTRY | 1 | Aug 12, 2021 | clinicaltrials |
| NCT03394885 | Atezolizumab With Neoadjuvant Chemotherapy for Patients With Newly-Diagnosed Advanced-Stage Ovarian Cancer(AdORN) | completed | Phase 1 / Phase 2 | 18 | Duke UniversityOTHER | 1 | Aug 12, 2021 | clinicaltrials |
| NCT00574678 | Analyzing the Composition of Tears to Identify Cancer(ACT) | completed | Phase 1 / Phase 2 | 150 | University of ArkansasOTHER | 1 | Aug 5, 2021 | clinicaltrials |
| NCT00806156 | Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Ovarian Cancer | completed | Phase 2 | 178 | Nektar TherapeuticsINDUSTRY | 3 | Jul 12, 2021 | clinicaltrials |
| NCT00945191 | Combination Chemotherapy With CS-1008 to Treat Ovarian Cancer | completed | Phase 2 | 24 | Daiichi SankyoINDUSTRY | 1 | Apr 8, 2021 | clinicaltrials |
| NCT03901118 | Chiauranib in Combination With Chemotherapy in Patients With Ovarian Cancer | completed | Phase 2 | 47 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | Mar 19, 2021 | clinicaltrials |
| NCT02249013 | Short-course HIPEC in Advanced Epithelial Ovarian Cancer | completed | Phase 2 | 15 | Professor Fernando Figueira Integral Medicine InstituteOTHER | 0 | Mar 18, 2021 | clinicaltrials |
| NCT01610206 | A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer | completed | Phase 2 | 148 | Linda R DuskaOTHER | 1 | Feb 25, 2021 | clinicaltrials |
| NCT01989546 | Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations | completed | Phase 1 / Phase 2 | 9 | National Cancer Institute (NCI)NIH | 1 | Feb 23, 2021 | clinicaltrials |
| NCT01146795 | Neoadjuvant Therapy for Ovarian Cancer | completed | Phase 2 | 32 | Jason D. WrightOTHER | 1 | Feb 9, 2021 | clinicaltrials |
| NCT02022917 | Postoperative Adjuvant Chemotherapy With Bevacizumab and Maintenance Bevacizumab After Neoadjuvant Chemotherapy for Ovarian Cancer | completed | Phase 2 | 22 | Chang Gung Memorial HospitalOTHER | 1 | Jan 27, 2021 | clinicaltrials |
| NCT02725489 | Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers | completed | Phase 2 | 13 | Mary Crowley Medical Research CenterOTHER | 1 | Jan 27, 2021 | clinicaltrials |
| NCT03742713 | Efficacy Study of CPC634 (CriPec® Docetaxel) in Platinum Resistant Ovarian Cancer(CINOVA) | completed | Phase 2 | 25 | Cristal TherapeuticsINDUSTRY | 3 | Dec 28, 2020 | clinicaltrials |
| NCT00420381 | Evaluation of Enzastaurin in the Treatment of Persistent or Recurrent Ovarian or Primary Peritoneal Cancer | completed | Phase 2 | 28 | Eli Lilly and CompanyINDUSTRY | 1 | Dec 19, 2020 | clinicaltrials |
| NCT01519869 | Trial of Chemotherapy in Ovarian, Fallopian Tube and Peritoneal Carcinoma | completed | Phase 2 | 28 | Rachel MillerOTHER | 1 | Dec 14, 2020 | clinicaltrials |
| NCT02490488 | Masitinib in Combination With Gemcitabine in Advanced/Metastatic Epithelial Ovarian Cancer Patients | completed | Phase 2 / Phase 3 | 248 | AB ScienceINDUSTRY | 6 | Dec 8, 2020 | clinicaltrials |
| NCT00551070 | Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer | completed | Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | Dec 3, 2020 | clinicaltrials |
| NCT00227721 | Gemcitabine and Docetaxel in Treating Patients With Relapsed or Refractory Ovarian Epithelial or Peritoneal Cancer | completed | Phase 2 | 30 | Robert MorrisOTHER | 1 | Dec 2, 2020 | clinicaltrials |
| NCT02399592 | Tocotrienol as a Nutritional Supplement in Patients With Advanced Ovarian Cancer(Toco-Ovar) | completed | Phase 2 | 23 | Vejle HospitalOTHER | 1 | Nov 30, 2020 | clinicaltrials |
| NCT02283658 | Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer | completed | Phase 2 | 20 | Mayo ClinicOTHER | 1 | Oct 23, 2020 | clinicaltrials |
| NCT00391118 | Comparing Two Treatments for Ovarian Cancer: Standard Chemotherapy Plus Enzastaurin, or Placebo ("Sugar Pill") | completed | Phase 2 | 153 | Eli Lilly and CompanyINDUSTRY | 5 | Oct 19, 2020 | clinicaltrials |
| NCT02560337 | Cabazitaxel in Patients With Recurrent Ovarian Cancer After Failure of Standard Therapy.(CaTo-ROC) | completed | Phase 2 | 26 | Vejle HospitalOTHER | 1 | Oct 8, 2020 | clinicaltrials |
| NCT01199263 | Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 108 | National Cancer Institute (NCI)NIH | 1 | Sep 16, 2020 | clinicaltrials |
| NCT01611558 | Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer | completed | Phase 2 | 40 | Bristol-Myers SquibbINDUSTRY | 1 | Jul 13, 2020 | clinicaltrials |
| NCT01580696 | Phase I/IIa Trial of Folate Binding Protein Vaccine in Ovarian Cancer | completed | Phase 1 / Phase 2 | 51 | COL George Peoples, MD, FACSFED | 1 | May 4, 2020 | clinicaltrials |
| NCT01711970 | A Phase I/II Trial of VB-111 and Paclitaxel for Recurrent Platinum-Resistant Müllerian Cancer | completed | Phase 1 / Phase 2 | 38 | Vascular Biogenics Ltd. operating as VBL TherapeuticsINDUSTRY | 1 | Apr 24, 2020 | clinicaltrials |
| NCT00030446 | Erlotinib and Carboplatin in Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 50 | NCIC Clinical Trials GroupNETWORK | 1 | Apr 8, 2020 | clinicaltrials |
| NCT00003892 | ISIS 5132 in Treating Patients With Metastatic or Recurrent Ovarian Cancer | completed | Phase 2 | 22 | NCIC Clinical Trials GroupNETWORK | 3 | Apr 6, 2020 | clinicaltrials |
| NCT00010179 | Lurtotecan Liposome in Treating Patients With Advanced or Recurrent Ovarian Epithelial Cancer | completed | Phase 2 | 81 | NCIC Clinical Trials GroupNETWORK | 2 | Apr 6, 2020 | clinicaltrials |
| NCT00305695 | Zoledronate or Observation in Maintaining Bone Mineral Density in Patients Who Are Undergoing Surgery to Remove Both Ovaries | completed | Phase 2 | 160 | Gynecologic Oncology GroupNETWORK | 1 | Mar 24, 2020 | clinicaltrials |
| NCT01716715 | Cabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer | completed | Phase 2 | 111 | National Cancer Institute (NCI)NIH | 1 | Mar 10, 2020 | clinicaltrials |
| NCT02315430 | Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 13 | National Cancer Institute (NCI)NIH | 1 | Mar 10, 2020 | clinicaltrials |
| NCT00979992 | Sunitinib Malate in Treating Patients With Persistent or Recurrent Clear Cell Ovarian Cancer | completed | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 2 | Feb 19, 2020 | clinicaltrials |
| NCT01091636 | Intraoperative Hyperthermic Intraperitoneal Chemotherapy With Ovarian Cancer | completed | Phase 2 / Phase 3 | 184 | National Cancer Center, KoreaOTHER_GOV | 1 | Feb 17, 2020 | clinicaltrials |
| NCT01065441 | Experimental Therapeutic Cancer Vaccine Created In-situ in Patients With Stage II-Stage IV Cancer | completed | Phase 1 / Phase 2 | 9 | Michael Har-NoyINDUSTRY | 1 | Jan 22, 2020 | clinicaltrials |
| NCT03166891 | Phase Ib Study of Chiauranib in Patients With Ovarian Cancer | completed | Phase 1 / Phase 2 | 25 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | Jan 18, 2020 | clinicaltrials |
| NCT00479817 | Phase 2 AMG 386 in Comb. Paclitaxel for Subjects With Advanced Recurrent Epithelial Ovarian or Primary Peritoneal Cancer | completed | Phase 2 | 161 | AmgenINDUSTRY | 0 | Dec 18, 2019 | clinicaltrials |
| NCT00214058 | Weekly Carboplatin/Docetaxel for Recurrent Ovarian/Peritoneal Cancer | completed | Phase 2 | 36 | University of Wisconsin, MadisonOTHER | 1 | Nov 19, 2019 | clinicaltrials |
| NCT00445887 | Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer | completed | Phase 2 | 60 | Gynecologic Oncology GroupNETWORK | 1 | Nov 19, 2019 | clinicaltrials |
| NCT03452982 | Sentinel Lymph Node in Early Ovarian Cancer(SENTOV) | completed | Phase 2 | 20 | Instituto de Investigacion Sanitaria La FeOTHER | 1 | Oct 18, 2019 | clinicaltrials |
Data updated 22 days agoSource updated Feb 4, 2022source: clinicaltrials